HealthQuest Capital Research
Investment Thesis
HealthQuest Capital is a healthcare-only growth investor founded in 2012. It provides growth capital to commercial-stage companies that are transforming healthcare, and says it looks for businesses that improve patient outcomes and raise the efficiency of healthcare delivery. The firm describes its approach as investing at the intersection of healthcare subsectors, across both newer delivery models and traditional approaches. Its stated mission is to contribute to broadly improving people's lives through healthcare innovation while generating outsized risk-adjusted returns for its stakeholders.
Stage Focus
HealthQuest focuses primarily on commercial-stage companies that are ready to scale. It runs two strategies, Growth Equity and Tactical Opportunities, which let it use a range of structures tailored to each company. It is not a pre-seed or seed fund. Founders should expect to show commercial traction before approaching the firm.
Check Size
HealthQuest does not publish a check size range. Its flagship Fund IV closed at $675 million in May 2022, and the firm reports roughly $2 billion in assets under management across 52 portfolio companies, so its positions are growth-sized rather than early-stage checks.
Sector Focus
The firm invests across the healthcare landscape:
- Healthcare services
- Healthcare IT
- Medical devices
- Diagnostics
- Pharma services
The portfolio spans value-based care and chronic care (Somatus, Thyme Care, CopilotIQ, Inbound Health), medical technology (HistoSonics, OrganOx, Pulmonx, Trice Medical, Magnolia Medical Technologies), diagnostics and life-science tools (Rarecyte, Perspectum, Lunit), telehealth and consumer health (Amwell, Everly Health, Remedy Meds, Thirty Madison), and provider platforms (American Oncology Network, ENT Specialty Partners).
Lead Tendency
HealthQuest backs companies with significant capital and operating support, and it has led rounds, including a $142 million equity financing in February 2025. It describes itself as an active partner rather than a spectator of its portfolio.
Recent Activity
The firm has had a strong run of exits. In 2025, Terumo agreed to acquire OrganOx (August), HistoSonics was acquired by a consortium of investors at a $2.25 billion valuation (August), Remedy Meds agreed to acquire Thirty Madison (September), and Truven acquired Springbuk (September). In November 2024, Boston Scientific agreed to acquire Cortex. HealthQuest reports 23 total exits. Managing Partner Garheng Kong was named among the top healthcare investors of 2025 by GrowthCap.
Portfolio Highlights
- HistoSonics, acquired in 2025 at $2.25 billion
- OrganOx, being acquired by Terumo
- Thirty Madison, being acquired by Remedy Meds
- Amwell, Castle Biosciences and Lunit, which reached public markets
- Current holdings include 83bar, Ajax Health, Alcresta Therapeutics, CopilotIQ, Everly Health, Somatus, Thyme Care and Tiger Connect
Team
The investment team is led by a mix of physicians, scientists and operators.
- Garheng Kong, Founding Managing Partner
- Randy Scott, Founding Partner
- David Kabakoff, Founding Senior Partner
- Sam Brasch, Partner
- Sharath Reddy, Partner
- Nate Burns, Partner
- Witney McKiernan, Partner
- Jared Teo, Managing Director, Investment Execution
- Neil Parikh and Emily Zhen, Principals
The firm cites more than 300 years of combined operating and investing experience. It also works with operating partners, an Industry Advisory Board of former healthcare executives (including former CEOs of Becton Dickinson, Medtronic, Cardinal Health and LabCorp) and a Healthcare IT Council of health-system technology leaders.
Decision Process
HealthQuest makes decisions as a partnership. Its investment team works with its advisory boards on diligence and company support.
Founder Preferences
The firm looks for commercially proven healthcare companies with a path to scale, where its network of health-system, payer and employer relationships can help expand market presence. It cites reach of about 104 million patients, more than 3,000 hospital partners and about 6,500 employer partners across its portfolio.
Geographic Focus
HealthQuest invests across the United States and has backed companies in Europe and Asia, including OrganOx in the UK, Perspectum in the UK and Lunit in South Korea. It does not publish a geographic restriction.